UNICREDIT BANK/CALL/NOVO-NORDISK B/600/0.2/18.12.24 | Market Closed - BOERSE MUENCHEN 01:16:30 29/06/2024 am IST | ||
| 10.9 EUR | -1.27% |
|
| Current month | +21.52% | ||
| 1 month | +23.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 10.9 | -1.27% |
| 27/24/27 | 11.04 | +0.45% |
| 26/24/26 | 10.99 | -4.85% |
| 25/24/25 | 11.55 | +9.27% |
| 24/24/24 | 10.57 | -0.56% |
Real-time BOERSE MUENCHEN
Last update June 29, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HC7P39 |
| ISIN | DE000HC7P391 |
| Date issued | 26/06/2023 |
| Strike | 600 kr |
| Maturity | 18/12/2024 (173 Days) |
| Parity | 5 : 1 |
| Emission price | 1.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.65 € |
|---|---|
| Lowest since issue | 1.3 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
